Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy

Abstract Blood-based biomarkers reflect systemic inflammation status and have prognostic predictive value in solid malignancies. As a recently defined biomarker, Pan-Immune-Inflammation-Value (PIV) integrates different peripheral blood cell subpopulations. This retrospective study of collected data aimed to assess whether PIV may predict the pathological complete response (pCR) neoadjuvant chemotherapy (NAC) Turkish women with breast cancer. The consisted 743 patients cancer who were scheduled undergo NAC before attempting cytoreductive surgery. A pre-treatment count was obtained two weeks preceding NAC, blood-based calculated from absolute counts relevant populations. pCR as absence tumor cells both mastectomy specimen lymph nodes. Secondary outcome measures included disease-free survival (DFS) overall (OS). One hundred seven (14.4%) had pCR. In receiver operating characteristic analysis, optimal cut-off values for neutrophile-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte (MLR), platelet-to-lymphocyte (PLR), PIV, Ki-67 index determined ? 2.34, 0.22, 131.8, 306.4, 27, respectively. clinical (T) stage, NLR, MLR, PLR, estrogen receptor (ER) status, human epidermal growth factor receptor-2 (HER-2) significantly associated univariate analyses. However, multivariate analysis revealed that T ER HER-2 independent predictors Moreover, low group better DFS OS than those high ( p = 0.034, 0.028, respectively). Based on our results, seems predictor survival, outperforming PLR predicting received NAC. further studies are needed confirm findings.